Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial
Listen to this summary
The authors aimed to investigate the impact of genetic risk factors on treatment outcomes for early-stage chronic lymphocytic leukemia (CLL) patients receiving ibrutinib versus placebo in the GCLLSG CLL12 trial. They found that while ibrutinib improved event-free survival (EFS) in certain genetic subgroups, such as those with U-IGHV and del(11q) mutations, it did not provide overall survival (OS) benefits across any genetic subgroup, reinforcing the watch-and-wait strategy for asymptomatic early-stage CLL patients, particularly those with del(17p) or TP53 mutations.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Blood
View all →Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 24, 2026 · Blood
Direct and indirect regulation of fetal globin transcript by RNA-binding protein IGF2BP1
Jun 22, 2026 · Blood
Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration
More in Internal Medicine
View all →Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 24, 2026 · Journal of hepatology
Regression of liver cirrhosis
Jun 24, 2026 · Journal of addiction medicine
Medicaid Prior Authorization and Discontinuation of Buprenorphine
Jun 24, 2026 · Journal of addiction medicine
Implementation of Dyadic Care to Support Clinical, Administrative, and Service Wraparound Needs for the Opioid-Exposed Mother and Infant
Jun 24, 2026 · Critical care medicine
Ethical Implications of the Slow Code: A Systematic Review of Ethics of Slow Codes in U.S. Hospitals
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
